๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Jinan
Clinical trial register · China

Clinical Trials in Jinan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Qilu Hospital of Shandong University114 Qianfoshan Hospital32 Shandong Cancer Hospital and Institute31 AstraZeneca26 Shandong University26
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Jinan

785 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
NCT04892173Carcinoma, Squamous Cell
DrugsJNJ-90301900·Pemetrexed
Johnson & Johnson Enterprise Innovation Inc.
Phase 3
500
Bengbu, Changsha, Chengdu, Dongguan, Fuzhou, Guangzhou, Jinan, Linyi
2021-12-10
Active, closed
SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.
NCT05020457Non Small Cell Lung Cancer
DrugsSI-B001·Paclitaxel
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
69
Chongqing, Guangzhou, Guilin, Jinan, Taizhou
2021-12-07
Active, closed
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
NCT05112965Neoplasms
DrugsEnzalutamide·Atezolizumab·Pemetrexed·Bevacizumab
Hoffmann-La Roche
Phase 3
49
Guangzhou, Harbin, Wuhan, Jinan, Hangzhou, Beijing, Changchun, Changsha
2021-12-01
Recruiting
A Cohort of Patients Undergoing Percutaneous Coronary Intervention
NCT05719545Acute Coronary Syndrome, Percutaneous Coronary Intervention, Myocardial Infarction, Unstable Angina
Su Guohai
Observational
10,000
Jinan
2021-12-01
Recruiting
Cardiac Magnetic Resonance-Clinical Prediction Model-Dilated Cardiomyopathy
NCT07527715Cardiomyopathy, Dilated, Prognosis, Magnetic Resonance Imaging, Cardiac, Death, Sudden, Cardiac
Shandong Provincial Hospital
Observational
2,000
Jinan
2021-12-01
Recruiting
Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
NCT06021678CD20-positive Non-Hodgkin Lymphoma
Guangzhou Excelmab Inc.
Phase 1/2
415
Zhengzhou, Jinan, Shanghai, Tianjin
2021-11-12
Active, closed
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
NCT05048797Locally Advanced or Metastatic Non-Small Cell Lung Cancer
DrugsTrastuzumab deruxtecan·Pemetrexed·Cisplatin·Carboplatin
AstraZeneca
Phase 3
454
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan
2021-10-28
Active, closed
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
NCT05043090Papillary Renal Cell Carcinoma
DrugsSavolitinib·Sunitinib·Durvalumab
AstraZeneca
Phase 3
148
Beijing, Changsha, Chongqing, Harbin, Jinan, Nanjing, Shanghai, Shenyang
2021-10-28
Recruiting
Use of Determine Learning-based Cardiodynamicsgram (CDG) for Rapid and Precise Stratification of Chest Pain in Emergency Department
NCT06669884Chest Pain, Acute Coronary Syndrome
Qilu Hospital of Shandong University
Observational
8,000
Jinan
2021-10-28
Recruiting
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
NCT05099172Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation
Bayer
Phase 1/2
400
Beijing, Fuzhou, Harbin, Wuhan, Changsha, Nanjing, Taizhou, Jinan
2021-10-25
Active, closed
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
NCT04895696Systemic Lupus Erythematosus
Beeline Medicines Corporation
Phase 2
248
Beijing, Shenzhen, Nanjing, Suzhou, Changchun, Dalian, Jinan, Jining
2021-10-11
Active, closed
A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)
NCT04765059Non-small Cell Lung Cancer
DrugCarboplatin
AstraZeneca
Phase 3
98
Beijing, Ganzhou, Guangzhou, Jinan, Shenyang, Tianjin, Zhengzhou
2021-09-12
Active, closed
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
NCT04919811Non Small Cell Lung Cancer
DrugTaletrectinib
Nuvation Bio Inc.
Phase 2
217
Beijing, Zhengzhou, Shanghai, Changsha, Chengdu, Jinan, Wuhan
2021-09-01
Active, closed
A Multicenter Randomized Open-label Study of Diammonium Glycyrrhizinate Enteric-coated Capsule Plus DXM Versus DXM in Treatment of ITP
NCT05023915Immune Thrombocytopenia
Shandong University
Phase 2
106
Jinan, Qingdao
2021-08-21
Active, closed
China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT06868654Multiple Myeloma
DrugsBelantamab mafodotin·Bortezomib·Daratumumab·Dexamethasone
GlaxoSmithKline
Phase 3
72
Beijing, Changchun, Guangzhou, Hangzhou, Jinan, Nanjing, Shenyang, Suzhou
2021-07-28
Recruiting
Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma
NCT04888429Sarcomatoid Carcinoma of Lung
DrugsFamitinib·Tislelizumab
Qian Chu
Phase 2
28
Xiamen, Zhengzhou, Wuhan, Changsha, Jinan
2021-07-19
Recruiting
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
NCT04951622Myasthenia Gravis
DrugNipocalimab
Janssen Research & Development, LLC
Phase 3
199
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan
2021-07-15
Recruiting
Efficacy and Safety of Gushen Antai Pill on Ongoing Pregnancy Rate in Women With Normal Ovarian Reserve Undergoing IVF-ET
NCT04872660Infertility, Female
Shandong University of Traditional Chinese Medicine
Phase 4
800
Jinan
2021-06-15
Active, closed
Guo's Aortic Arch Reconstruction :The Prospective ,Multiple Center Study About the Safety and Efficacy of WeFlow-Arch Modeler Embedded Branch Stent Graft System (GIANT Study)
NCT04765592Aortic Arch Aneurysm
Hangzhou Endonom Medtech Co., Ltd.
Not applicable
88
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Kunming
2021-06-07
Recruiting
Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma
NCT04716686Endometrial Carcinoma, Serous Carcinoma
DrugNiraparib
Shandong University
Phase 2
83
Jinan
2021-06-01
Recruiting
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
NCT04811560Acute Leukemia
DrugBleximenib
Janssen Research & Development, LLC
Phase 1/2
420
Beijing, Changchun, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing
2021-05-19
Active, closed
An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib
NCT04764188NSCLC
DrugAlectinib
Hoffmann-La Roche
Observational
800
Changsha, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Nanning, Taiyuan
2021-05-10
Recruiting
Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line Chemoradiotherapy
NCT04829708Limited Stage Small Cell Lung Cancer
Shandong Cancer Hospital and Institute
Phase 3
534
Jinan
2021-04-26
Recruiting
Tubeless Surgery With Impaired Pulmonary Function
NCT06848751Lung Function Decreased, Surgery
The Second Hospital of Shandong University
Not applicable
45
Jinan
2021-04-10
Recruiting
Oncologic Outcomes of Single-incision Versus Conventional Laparoscopic Surgery for Colorectal Cancer
NCT04527861Colorectal Cancer, Colon Cancer, Rectal Cancer
Ruijin Hospital
Not applicable
710
Lanzhou, Shenyang, Jinan, Chengdu, Hangzhou, Shanghai
2021-04-08
Recruiting
A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)
NCT06189391Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
DrugMK-1045
MSD R&D (China) Co., Ltd.
Phase 1
100
Beijing, Xiameng, Guangzhou, Shijiazhuang, Zhengzhou, Nanchang, Changchun, Jinan
2021-03-16
Recruiting
Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer
NCT07320586Gastric Cancer, Second-line Therapy
DrugsNab-paclitaxel·Tislelizumab
Shandong Tumor Hospital
Phase 2
40
Jinan
2021-03-01
Active, closed
Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A
NCT04644575Hemophilia A
DrugEfanesoctocog alfa
Bioverativ, a Sanofi company
Phase 3
261
Beijing, Guangzhou, Hangzhou, Jinan, Kunming, Lanzhou, Suzhou
2021-02-23
Recruiting
Raman Spectroscopy Diagnosis of Kidney Diseases
NCT06760845IgA Nephropathy (IgAN), Membranous Nephropathy, Diabetic Nephropathy, Focal Segmental Glomerulosclerosis (FSGS)
Zunsong Wang
Observational
200
Jinan
2021-02-01
Recruiting
Quinoa Improves Glycolipid Metabolism and Glucose Fluctuation Based on ฮฒ-Cell Function in Early-stage Type 2 Diabetes
NCT07329231Type 2 Diabetes Mellitus (T2DM)
Qilu Hospital of Shandong University
Not applicable
60
Jinan
2021-01-10
Recruiting
Antiepileptic Drugs in Elderly Patients
NCT05459597Seizure, Epileptic
Wei Zhao
Observational
500
Jinan
2021-01-01
Recruiting
ML-Based ABPA Recurrence Prediction and Clinical Utility
NCT07714863ABPA, Allergic Bronchopulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis (ABPA), Acute Exacerbation
Qianfoshan Hospital
Observational
200
Jinan
2021-01-01
Recruiting
Antineoplastic Drugs in Elderly Patients
NCT05467189Cancer
DrugsLapatinib·Ceritinib·Busulfan·Afatinib
Shandong University
Observational
500
Jinan
2021-01-01
Recruiting
Multi-Omics Inflammatory Phenotype for ABPA Recurrence Risk Prediction
NCT07611838Allergic Bronchopulmonary Aspergillosis (ABPA), Machine Learning, Multi-omics, Multicenter Study
Qianfoshan Hospital
Observational
300
Jinan
2021-01-01
Active, closed
Optimal Ablation Strategies for Persistent AF With HF
NCT07153718Heart Failure, Persistent Atrial Fibrillation
Xu Liu
Not applicable
300
Anqing, Wuhan, Changshu, Xuzhou, Jinan, Jining, Yuhuan, Shanghai
2021-01-01
Active, closed
Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
NCT04562766Immune Thrombocytopenia
DrugRilzabrutinib
Principia Biopharma, a Sanofi Company
Phase 3
232
Wuhan, Shenyang, Xi'an, Jinan, Tianjin, Kunming, Hangzhou, Hefei
2020-12-14
Active, closed
Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
NCT04639986Metastatic Breast Cancer
DrugsEribulin mesylate·Vinorelbine·Sacituzumab Govitecan·Gemcitabine
Gilead Sciences
Phase 3
331
Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan
2020-11-23
Recruiting
Left Atrial Appendage Closure as Secondary Prevention of Atrial Fibrillation-related Embolic Events
NCT04559243Non-valvular Atrial Fibrillation, Embolic Stroke
Lifetech Scientific (Shenzhen) Co., Ltd.
Observational
579
Jinan, Shanghai, Mianyang, Wenzhou
2020-11-12
Recruiting
Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT04586478Non-Hodgkin's Lymphoma
DrugSingle of CNCT19
Juventas Cell Therapy Ltd.
Phase 2
60
Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Jinan, Shanghai, Chengdu
2020-10-26
Active, closed
Myasthenia Gravis Inebilizumab Trial
NCT04524273Myasthenia Gravis
DrugInebilizumab
Amgen
Phase 3
238
Beijing, Guiyang, Hunan, Jinan, Shanghai, Suzhou, Tianjin, Xi'an
2020-10-15
Active, closed
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
NCT04529772Diffuse Large B-Cell Lymphoma
DrugsAcalabrutinib·Vincristine·Doxorubicin·Prednisone
Acerta Pharma BV
Phase 3
611
Beijing, Changchun, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Luoyang
2020-10-08
Active, closed
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance
NCT04285086Essential Thrombocythemia
DrugsAnagrelide·Ropeginterferon alfa-2b
PharmaEssentia
Phase 3
174
Beijing, Chongqing, Guangzhou, Wuhan, Suzhou, Shenyang, Xi'an, Jinan
2020-08-25
Active, closed
The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
NCT04233346Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia
Otsuka Beijing Research Institute
Phase 2
93
Hefei, Guangzhou, Wuhan, Changsha, Suzhou, Shenyang, Jinan, Taiyuan
2020-07-09
Recruiting
Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer
NCT04688801Esophageal Cancer, Gastroesophageal Cancer, Immunotherapy, Adjuvant
The Second Hospital of Shandong University
Not applicable
200
Jinan
2020-07-01
Recruiting
Robotic Versus Video-assisted Lobectomy/Segmentectomy for Lung Surgery
NCT05270616Lung Diseases, Surgery
The Second Hospital of Shandong University
Not applicable
800
Jinan
2020-06-01
Active, closed
Angiography-Derived FFR And IVUS for Clinical Outcomes in Patients With Coronary Artery Disease
NCT04397211Coronary Artery Disease
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,872
Hangzhou, Beijing, Guangdong, Huzhou, Jinan, Jinhua, Kunming, Nanchang
2020-05-29
Active, closed
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT04246047Multiple Myeloma
DrugsBelantamab mafodotin·Bortezomib·Daratumumab·Dexamethasone
GlaxoSmithKline
Phase 3
494
Beijing, Jinan, Shenyang
2020-05-07
Active, closed
Effectiveness, Safety, and Economic Evaluation of Goserelin Microspheres for Injection and Goserelin Sustained-Release Implants in Prostate Cancer Patients: A Real-World Study
NCT06929884Prostate Cancers
Qianfoshan Hospital
Observational
400
Jinan
2020-04-02
Active, closed
A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
NCT04280081Solid Tumor, Medullary Thyroid Cancer
DrugSelpercatinib
Eli Lilly and Company
Phase 2
77
Beijing, Guangzhou, Changsha, Changchun, Jinan, Shanghai, Tianjin, Hangzhou
2020-03-16
Recruiting
Video-assisted Thoracoscopic Thymectomy Versus Subxiphoid Procedure
NCT04223466Thymectomy
The Second Hospital of Shandong University
Not applicable
100
Jinan
2020-01-07
Recruiting
Correlation Between Microbial Infection and Lumbar Degenerative Disease Based on High-throughput Gene Sequencing
NCT06075979Lumbar Degenerative Diseases, Gene Product Sequence Variation
HaoxuanZhang
Not applicable
200
Jinan
2020-01-02
By invitation
The Study of INTRA Spine Non Fusion Technique in the Treatment of Lumbar Degenerative Disease
NCT06075966Lumbar Degenerative Disease
Qianfoshan Hospital
Not applicable
60
Jinan
2020-01-01
By invitation
Research on Early Recurrence of Locally Advanced Gastric Cancer Based on CT Radiomics Prediction
NCT07683195Gastric Cancer
Liu Yang
Observational
900
Jinan
2020-01-01
Active, closed
The Effect of the Application of Head Mounted Magnifying Glasses on Postoperative PTH Changes in Thyroid Surgery: Stage II
NCT06838728Thyroid Surgery
Shandong Provincial Hospital
Not applicable
2,000
Jinan
2020-01-01
Recruiting
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
NCT04202341Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Observational
500
Chengdu, Beijing, Changchun, Guangzhou, Jinan, Nanchang, Qingdao, Shijiazhuang
2019-12-02
Recruiting
Lung Surgery With Enhanced Recovery VS. Lung Surgery Without Enhanced Recovery
NCT04451473Lung Cancer, Surgery, ERAS
The Second Hospital of Shandong University
Not applicable
350
Jinan
2019-10-08
Recruiting
Self-reported Outcomes of Patients in ERAS Nursing
NCT05528484Enhanced Recovery After Surgery
The Second Hospital of Shandong University
Not applicable
600
Jinan
2019-10-01
Recruiting
Segmentectomy Versus Lobectomy for Lung Adenocarcinoma โ‰ค 2cm
NCT04937283Lung Adenocarcinoma
Shanghai Pulmonary Hospital, Shanghai, China
Not applicable
690
Hefei, Nanyang, Nantong, Xuzhou, Yancheng, Jinan, Shanghai, Hangzhou
2019-10-01
Active, closed
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
NCT04077463Carcinoma, Non-Small-Cell Lung
DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin
Janssen Research & Development, LLC
Phase 1
701
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan
2019-09-04
Active, closed
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
NCT04077723Lymphoma, Non-Hodgkin
DrugsGlofitamab·Tocilizumab·Obinutuzumab
Hoffmann-La Roche
Phase 1/2
498
Beijing, Jinan, Shanghai, Xiamen
2019-08-13
Active, closed
Quantitative Flow Ratio (QFR) Guided Coronary Artery Bypass Grafting for Patients Undergoing Primary Valve Surgery With Concomitant Coronary Artery Disease
NCT03977129Primary Valvular Heart Disease With Comorbid Coronary Artery Disease, Planned to Undergo Elective On-pump Valve Surgery Due to Primary Mitral and/or Aortic Valvular Heart Disease
Ruijin Hospital
Not applicable
792
Hefei, Fuzhou, Zhengzhou, Changsha, Jinan, Qingdao, Shanghai, Tianjin
2019-08-04
Active, closed
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
NCT04008797Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms
DrugsE7386·Doxorubicin·Lenvatinib·Paclitaxel
Eisai Inc.
Phase 1/2
301
Beijing, Changchun, Fuzhou, Guangzhou, Jinan, Kunming, Shanghai, Shenzhen
2019-07-11
Recruiting
Construction of a Multi-center Clinical Research Collaboration Network for Children with Congenital Heart Disease in China
NCT06885307Congenital Heart Disease (CHD)
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Observational
35,000
Wuhan, Xining, Shanghai, Kunming, Wenzhou, Jinan
2019-06-01
Active, closed
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
NCT03833154Carcinoma, Non-Small-Cell Lung
DrugDurvalumab
AstraZeneca
Phase 3
724
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Hangzhou, Hefei, Jinan
2019-03-06
Active, closed
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX
NCT03754790Hemophilia
DrugFitusiran
Genzyme, a Sanofi Company
Phase 3
281
Beijing, Changsha, Chengdu, Guangzhou, Guiyang, Hangzhou, Jinan, Kunming
2019-01-09
Recruiting
Microvascular Angina Intervention With Compound Danshen Dripping Pill (MAIDS)
NCT06092736Microvascular Angina
Qilu Hospital of Shandong University
Phase 4
100
Jinan
2018-12-18
Active, closed
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
NCT03682068Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer
DrugsTremelimumab·Durvalumab·Gemcitabine·Cisplatin
AstraZeneca
Phase 3
1,246
Beijing, Changchun, Changsha, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan
2018-09-27
Recruiting
The Clinical Features and Pregnancy Outcomes of CTD Patients
NCT04918524Connective Tissue Diseases, Pregnancy Related
DrugsHydroxychloroquine·Aspirin·Prednisone
Qilu Hospital of Shandong University
Observational
126
Jinan
2018-09-11
Active, closed
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
NCT03456076Carcinoma, Non-Small-Cell Lung
DrugsVinorelbine·Gemcitabine·Pemetrexed·Cisplatin
Hoffmann-La Roche
Phase 3
257
Beijing, Changchun, Chengdu, Fujian, Guangzhou, Hangzhou, Jinan, Shanghai
2018-08-16
Active, closed
A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)
NCT03521154Non Small Cell Lung Cancer (Stage III)
DrugOsimertinib
AstraZeneca
Phase 3
216
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Linhai
2018-07-19
Recruiting
Treatment and Clinical Outcomes Among SLE Patients in Pregnancy
NCT04976465Systemic Lupus Erythematosus, Pregnancy Related
Qilu Hospital of Shandong University
Phase 1
200
Jinan
2018-01-01
Active, closed
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT03178552Non-Small Cell Lung Cancer
DrugsCobimetinib·Vemurafenib·Divarasib·Entrectinib
Hoffmann-La Roche
Phase 2/3
1,000
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing
2017-09-22
Active, closed
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
NCT03155997Breast Cancer
DrugAbemaciclib
Eli Lilly and Company
Phase 3
5,637
Beijing, Fuzhou, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing, Jinan
2017-07-12
Recruiting
Multicenter Cohort Study on Osteoporosis
NCT02958020Osteoporosis
Shanghai University of Traditional Chinese Medicine
Observational
50,000
Shenzhen, Ganzhou, Jinan, Kunming, Beijing, Changchun, Guangzhou, Lanzhou
2016-11
Not yet open
The Influence of Helicobacter Pylori Eradication on Gastric Pathology: a Long-term, Prospective Cohort Study
NCT02933229Helicobacter Pylori, the Operative Link on Gastric Intestinal Metaplasia, Operative Link on Gastric Intestinal Assessment
Shandong University
Phase 4
300
Jinan
2016-10
Recruiting
TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors
NCT02429687Ovarian Germ Cell Cancer, Ovarian Neoplasms, Ovarian Cancer
DrugsBleomycin·Etoposide·Cisplatin·Carboplatin
Beihua Kong
Phase 3
129
Jinan
2015-04
Recruiting
TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors
NCT02429700Ovarian Sex Cord Stromal Tumor, Ovarian Neoplasms, Ovarian Cancer
DrugsBleomycin·Etoposide·Cisplatin·Carboplatin
Beihua Kong
Phase 3
132
Jinan
2015-04
Active, closed
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
NCT02032823Breast Cancer
DrugOlaparib
AstraZeneca
Phase 3
1,837
Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Jinan, Nanjing
2014-04-22
Active, closed
The Safety of Ovarian Preservation in Stage IA Endometrial Carcinoma
NCT01820884Endometrial Neoplasms
Ding Ma
Not applicable
240
Wuhan, Jinan, Hangzhou
2012-11
Active, closed
The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma
NCT01820858Endometrial Neoplasms
DrugsParaplatin·Carboplatin·Paclitaxel
Ding Ma
Phase 3
300
Wuhan, Jinan, Hangzhou
2012-11
Recruiting
Iodine Nutrition Status and Clinical Characteristics of Thyroid Cancer
NCT06623500Thyroid Cancer
Shandong Provincial Hospital
Observational
1,600
Jinan
2012-01-01
Recruiting
The Biological Rhythm of Human Metabolite
NCT03669809Rhythm Nodal, Metabolism and Nutrition Disorder, Metabolism Disorder, Lipid
Shandong Provincial Hospital
Observational
200
Jinan
2011-05-01
Recruiting
Pompe Disease Registry Protocol
NCT00231400Glycogen Storage Disease Type II, Pompe Disease
Genzyme, a Sanofi Company
Observational
2,000
Beijing, Guangzhou, Jinan, Shanghai
2004-09-15
Recruiting
Fabry Disease Registry & Pregnancy Sub-registry
NCT00196742Fabry Disease
Genzyme, a Sanofi Company
Observational
9,000
Beijing, Hangzhou, Jinan, Nanjing, Shanghai
2001-07-31
Active, closed
Optimization of a Decision Formula for Optimal Timing of Immunosuppressive Therapy Initiation in Primary Membranous Nephropathy: A Multicenter Retrospective Cohort Study
NCT06924476Primary Membranous Nephropathy
Yipeng Liu
Observational
282
Jinan
1990-01-01
Rows per page Showing 701–785 of 785
Previous 6 7 8
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/jinan?page=8

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 785 of those studies with a site in Jinan.

How many clinical trials are recruiting in Jinan?

488 of the 785 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 130 have not yet opened recruitment, 149 are active but closed to new participants, and 18 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.